ANRG EPS of -4c beat estimates of -5c; revenue of $32.3M beat estimates of $27M. EBITDA of -$2.22M beat estimates of -$7.3M. A new contract in Spain was announced yesterday. It was a good quarter, with higher sales, better margins and a higher backlog. Backlog is $244M, up more than $100M this year alone. Revenue rose 37%. The new CEO's stragegy of 'capital light' growth is working very well. EBITDA improved but is still negative and we would like to see that change. Overall, the news is good and the outlook improving. The stock has been a long term disaster but there is a new team in town. Risks are very high still but we would consider it a HOLD today.
SPB EPS of -25c missed estimates of -11c; revenue of $432.2M missed estimates of $473.9M. EBITDA of $33.5M missed estimates by 27%. Guidance was affirmed, but several brokers did downgrade the stock or their target prices. Free cash flow and EBITDA did increase, which is positive. SPB bought and cancelled 3.2% of its shares and since November has cancelled 10%. Expected EBITDA growth is 8%. While a miss across most metrics, the stabilization here continues. The stock is cheap and not without potential. It is up 12% YTD. Another HOLD for now.